Original Article Entomotherapy bidirectional effect in chronic prostatitis and benign prostatic hyperplasia management

Cover Page

Cite item

Full Text

Abstract

Introduction. Antibiotic monotherapy does not provide sufficient effectiveness in any type of prostatitis. Thus, pathogenic treatment is required, but no definite guidelines on medication choice exist nowadays. Objective. To evaluate Adenoprosin entomotherapy effectiveness in patients with chronic abacterial prostatitis with signs of inflammatory process. Materials and methods. The study included 40 patients with chronic abacterial prostatitis, mean age of the patients was 36.2 years. Inclusion criteria: diagnosed chronic prostatitis (CP) 3a category, symptoms severity evaluated by NIH-CPSI total score more than 15 points, disease duration more than 6 months, leucocyte count in prostate fluid more than 15 cells. Baseline therapy was conducted for 1 month. Control group patients received only baseline treatment. Study group patients received Adenoprosin rectal suppositories daily for 30 days in addition to baseline treatment. Treatment results were evaluated right after therapy course was complete and 2 months after. Treatment effectiveness was evaluated by decrease of prostate fluid leucocyte count decrease, symptoms questionnaires NIH-CPSI and I-PSS, and urodynamics characteristics. Results. No statistically significant differences in frequency and severity of main symptoms were found at baseline, the study groups were identical. In 1/2 cases in both groups benign prostatic hyperplasia (BPH) was found in CP patients. After treatment was complete significant differences were found in parameters “pain”, “quality of life”, “urination disorders”, and in total score. Urination in study group was also improved more significantly that was confirmed with uroflowmetry results. International Prostate Symptom Score (I-PSS) confirmed that baseline treatment combined with entomotherapy was more effective. At follow-up after 2 months clinical and laboratory results ratio did not change significantly that illustrates delayed prolonged effect of Adenoprosin. Conclusion. In 1/2 patients with CP in our study BPH was diagnosed for the first time. We suggest that CH and BPH mask and confound each other’s course and that is why it is preferable to use medication with bidirectional effects. Key words: chronic prostatitis, chronic abacterial prostatitis, pathogenic treatment, entomotherapy, Adenoprosin, benign prostatic hyperplasia. For citation: Kulchavenya E.V., Breusov A.A. Entomotherapy bidirectional effect in chronic prostatitis and benign prostatic hyperplasia management. Consilium Medicum. 2020; 22 (6): 64-67. DOI: 10.26442/20751753.2020.6.200178

About the authors

Ekaterina V. Kulchavenya

Novosibirsk TB Research Institute; Novosibirsk State Medical University

Email: urotub@yandex.ru
д-р мед. наук, проф., гл. науч. сотр.

Aleksandr A. Breusov

Medical Center "BIOVER"

канд. мед. наук

References

  1. Liang CZ, Li HJ, Wang ZP et al. The prevalence of prostatitis-like symptoms in China. J Urol 2009; 182 (2): 558-63. doi: 10.1016/j.juro.2009.04.011
  2. Mi H, Chen K, Mo ZN. Epidemiological characteristics of chronic prostatitis in China. Zhonghua Nan Ke Xue 2012; 18 (7): 579-82.
  3. Tripp DA, Nickel JC, Pikard JL, Katz L. Chronic prostatitis-like symptoms in African males aged 16-19 years. Can J Urol 2012; 19 (1): 6081-7.
  4. Кульчавеня Е.В., Холтобин Д.П., Шевченко С.Ю. и др. Частота хронического простатита в структуре амбулаторного урологического приема. Экспериментальная и клиническая урология. 2015; 1: 16-9.
  5. Bartoletti R, Cai T, Mondaini N et al; Italian Prostatitis Study Group. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol 2007; 178 6): 2411-5; dis. 2415.
  6. Кульчавеня Е.В. Как повысить качество жизни больных хроническим простатитом. Справочник поликлинического врача. 2019; 4: 64-9.
  7. Mandar R, Korrovits P, Rahu K et al. Dramatically deteriorated quality of life in men with prostatitis-like symptoms. Andrology 2020; 8 (1): 101-9. doi: 10.1111/andr.12647 ИНФОРМАЦИЯ ОБ АВТОРАХ / INFORMATION ABOUT THE AUTHORS
  8. Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis 2018; 21 (3): 345-54. doi: 10.1038/s41391-018-0041-1
  9. Zhang JL, Yuan B, Wang MQ et al. Prostatic Artery Embolization for Benign Prostatic Hyperplasia: Bleomycin-Eluting versus Bland Microspheres in a Canine Model. J Vasc Interv Radiol 2020; 31 (5): 820-30. doi: 10.1016/j.jvir.2019.11.028
  10. Zhang M, Luo C, Cui K et al. Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model. World J Urol 2020 Jan 21. doi: 10.1007/s00345-020-03090-6
  11. Zhang J, Liang C, Shang X, Li H. Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Disease or Symptom? Current Perspectives on Diagnosis, Treatment, and Prognosis. Am J Mens Health 2020; 14 (1): 1557988320903200.
  12. Franco JVA, Turk T, Jung JH et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int 2020. doi: 10.1111/bju.14988
  13. Nickel JC. Chronic prostatitis/chronic pelvic pain syndrome: it is time to change our management and research strategy. BJU Int 2020; 125 (4): 479-80. doi: 10.1111/bju.15036
  14. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159: 1224-8.
  15. Shukla P, Gulwani HV, Kaur S. Granulomatous prostatitis: clinical and histomorphologic survey of the disease in a tertiary care hospital. Prostate Int 2017; 5 1): 29-34. doi: 10.1016/j.prnil.2017.01.003
  16. Кульчавеня Е.В. Контроль внелегочного туберкулеза в Сибири и на Дальнем Востоке. Проблемы туберкулеза и болезней легких. 2008; 85 (9): 16-9.
  17. Chen CH, Lin J, Lin JS, Chen YM. Mycobacterium abscessus complex bacteremia due to prostatitis after prostate biopsy. Indian J Tuberc 2016; 63 (4): 273-5. doi: 10.1016/j.ijtb.2015.07.014
  18. Кульчавеня Е.В., Жукова И.И. Внелегочный туберкулез - вопросов больше, чем ответов. Туберкулез и болезни легких. 2017; 95 (2): 59-63. doi: 10.21292/2075-1230-2017-95-2-59-63
  19. Cai T, Tamanini I, Kulchavenya E et al. The role of nutraceuticals and phytotherapy in the management of urinary tract infections: What we need to know? Archivo Italiano di Urologia e Andrologia. 2017; 89: 1-6. doi: 10.4081/aiua2017.1
  20. De Nunzio C, Giglio S, Stoppacciaro A et al. Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Oncotarget 2017 Feb 7. doi: 10.18632/oncotarget.15144. doi: 10.1177/1557988320903200
  21. Hajighorbani M, Ahmadi-Hamedani M, Shahab E et al. Evaluation of the protective effect of pentoxifylline on carrageenan-induced chronic non-bacterial prostatitis in rats. Inflammopharmacology 2017 Mar 9. doi: 10.1007/s10787-017-0335-2
  22. Han WJ, Guo YG, Wang YQ, Wang JW. The effectiveness of electrical stimulation for the management of benign prostatic hyperplasia: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020; 99 (19): e19921. doi: 10.1097/MD.0000000000019921
  23. Kim HB, Kim YI, Jeon JH et al. Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: Study protocol for an assessor-blinded, randomized controlled clinical trial. Medicine (Baltimore) 2020; 99 (15): e19678. doi: 10.1097/MD.0000000000019678
  24. Li J, Dong L, Yan X et al. Is Acupuncture Another Good Choice for Physicians in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome? Review of the Latest Literature. Pain Res Manag 2020; 2020: 921038. doi: 10.1155/2020/5921038
  25. Liu JW, Lin TC Naouar S et al. Spontaneous rupture into the peritoneal cavity: Unusual presentation of prostatic abscess. Int J Surg Case Rep 2017; 32: 73-5. doi: 10.1016/j.ijscr.2017.02.006
  26. Magri V, Wagenlehner FM, Marras E et al. Influence of infection on the distribution patterns of NIH-Chronic Prostatitis Symptom Index scores in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Exp Ther Med 2013; 6 (2): 503-8.
  27. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979; 21 6): 755-60. doi: 10.1016/s0022-5347(17)56980-3
  28. Mishra VC, Allen DJ, Nicolaou C et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007; 100 (2): 327-31. doi: 10.1111/j.1464-410X.2007.06910.x
  29. Robert G, Descazeaud A, Nicolaiew N et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 2009; 69 (16): 1774-80. doi: 10.1002/pros.21027
  30. Wu ZL, Yuan Y, Geng H, Xia SJ. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl 2012; 14 (2): 316-9. doi: 10.1038/aja.2011.154
  31. Bostanci Y, Kazzazi A, Momtahen S et al. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 2013; 23 (1): 5-10. doi: 10.1097/MOU.0b013e32835abd4a
  32. Ishola IO, Tijani HK, Dosumu OO et al. Atorvastatin attenuates testosterone-induced benign prostatic hyperplasia in rats: role of peroxisome proliferator-activated receptor-gamma and cyclo-oxygenase-2. Fundam Clin Pharmacol 2017; 31 (6): 652-62. doi: 10.1111/fcp.12301
  33. Jena AK, Vasisht K, Sharma N et al. Amelioration of testosterone induced benign prostatic hyperplasia by Prunus species. J Ethnopharmacol 2016; 190: 3-45. doi: 10.1016/j.jep.2016.05.052
  34. Dumbraveanu I, Ciuhrii C, Tanase A. Anti-inflammatory activity of Adenoprosin in nonbacterial prostatitis. Moldovan Medical Journal 2017; 60 (4): 4-10.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies